Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Dow
Boehringer Ingelheim
Farmers Insurance
Daiichi Sankyo
Citi
Mallinckrodt
Queensland Health
QuintilesIMS

Generated: October 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,368,469

« Back to Dashboard

Which drugs does patent 7,368,469 protect, and when does it expire?


Patent 7,368,469 protects ALTACE and is included in two NDAs.

This patent has forty-four patent family members in thirty-one countries.

Summary for Patent: 7,368,469

Title:Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
Abstract:Use of an inhibitor of the renin-angiotensin system or a pharmaceutically acceptable derivative thereof, optionally together with another antihypertensive, a cholesterol lowering agent, a diuretic or aspirin, in the manufacture of a medicament for the prevention of cardiovascular events; a method of preventing cardiovascular events comprising administering to a patient in need of such prevention an effective amount of an inhibitor of the renin angiotensin system or a pharmaceutically acceptable derivative thereof, optionally together with another antihypertensive, a cholesterol lowering agent, a diuretic or aspirin; and a combination product containing an an inhibitor of the renin-angiotensin system or a pharmaceutically acceptable derivative thereof and a cholesterol lowering agent.
Inventor(s): Scholkens; Bernward (Kelkheim, DE), Bender; Norbert (Hofheim, DE), Rangoonwala; Badrudin (Hofheim, DE), Dagenais; Gilles (St.-Nicholas, CA), Gerstein; Hertzel (Hamilton, CA), Yusuf; Salim (Carlisle, CA)
Assignee: Sanofi-Aventis Deutschland GmbH (Frankfurt, DE)
Application Number:11/490,061
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
King Pharms Llc
ALTACE
ramipril
CAPSULE;ORAL019901-001Jan 28, 1991ABRXYesNo► Subscribe► Subscribe METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH
King Pharms Llc
ALTACE
ramipril
CAPSULE;ORAL019901-002Jan 28, 1991ABRXYesNo► Subscribe► Subscribe METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH
King Pharms Llc
ALTACE
ramipril
CAPSULE;ORAL019901-003Jan 28, 1991ABRXYesNo► Subscribe► Subscribe METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH
King Pharms Llc
ALTACE
ramipril
CAPSULE;ORAL019901-004Jan 28, 1991ABRXYesYes► Subscribe► Subscribe METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH
King Pfizer
ALTACE
ramipril
TABLET;ORAL022021-001Feb 27, 2007DISCNYesNo► Subscribe► Subscribe METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH
King Pfizer
ALTACE
ramipril
TABLET;ORAL022021-002Feb 27, 2007DISCNYesNo► Subscribe► Subscribe METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH
King Pfizer
ALTACE
ramipril
TABLET;ORAL022021-003Feb 27, 2007DISCNYesNo► Subscribe► Subscribe METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH
King Pfizer
ALTACE
ramipril
TABLET;ORAL022021-004Feb 27, 2007DISCNYesNo► Subscribe► Subscribe METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,368,469

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria303800► Subscribe
Australia2005209687► Subscribe
Australia2009200746► Subscribe
Australia7649100► Subscribe
Bulgaria106360► Subscribe
Bulgaria110003► Subscribe
Bulgaria65474► Subscribe
Brazil0013704► Subscribe
Canada2382549► Subscribe
Canada2488370► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Daiichi Sankyo
Fish and Richardson
Federal Trade Commission
Queensland Health
Fuji
Express Scripts
Colorcon
Dow
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot